Cargando…
CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total‐Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investig...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043772/ https://www.ncbi.nlm.nih.gov/pubmed/30009207 http://dx.doi.org/10.1002/acn3.584 |
_version_ | 1783339352552636416 |
---|---|
author | Ermann, Natalia Lewczuk, Piotr Schmitz, Matthias Lange, Peter Knipper, Tobias Goebel, Stefan Kornhuber, Johannes Zerr, Inga Llorens, Franc |
author_facet | Ermann, Natalia Lewczuk, Piotr Schmitz, Matthias Lange, Peter Knipper, Tobias Goebel, Stefan Kornhuber, Johannes Zerr, Inga Llorens, Franc |
author_sort | Ermann, Natalia |
collection | PubMed |
description | Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total‐Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho‐Tau epitopes (non‐P‐Tau) in the discrimination between both diseases. Non‐P‐Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt–Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total‐Tau (90%), P‐Tau (62%) and 14‐3‐3 (91%). |
format | Online Article Text |
id | pubmed-6043772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60437722018-07-15 CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD Ermann, Natalia Lewczuk, Piotr Schmitz, Matthias Lange, Peter Knipper, Tobias Goebel, Stefan Kornhuber, Johannes Zerr, Inga Llorens, Franc Ann Clin Transl Neurol Brief Communications Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total‐Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho‐Tau epitopes (non‐P‐Tau) in the discrimination between both diseases. Non‐P‐Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt–Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total‐Tau (90%), P‐Tau (62%) and 14‐3‐3 (91%). John Wiley and Sons Inc. 2018-05-26 /pmc/articles/PMC6043772/ /pubmed/30009207 http://dx.doi.org/10.1002/acn3.584 Text en © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Brief Communications Ermann, Natalia Lewczuk, Piotr Schmitz, Matthias Lange, Peter Knipper, Tobias Goebel, Stefan Kornhuber, Johannes Zerr, Inga Llorens, Franc CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD |
title | CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
|
title_full | CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
|
title_fullStr | CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
|
title_full_unstemmed | CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
|
title_short | CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
|
title_sort | csf nonphosphorylated tau as a biomarker for the discrimination of ad from cjd |
topic | Brief Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043772/ https://www.ncbi.nlm.nih.gov/pubmed/30009207 http://dx.doi.org/10.1002/acn3.584 |
work_keys_str_mv | AT ermannnatalia csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT lewczukpiotr csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT schmitzmatthias csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT langepeter csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT knippertobias csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT goebelstefan csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT kornhuberjohannes csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT zerringa csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd AT llorensfranc csfnonphosphorylatedtauasabiomarkerforthediscriminationofadfromcjd |